

AMENDMENTS TO THE CLAIMS:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-12 (canceled).

Claim 13 (original): A purified monoclonal antibody which specifically recognizes a peptide having the amino acid sequence of SEQ ID NO:2.

Claim 14 (original): A purified monoclonal antibody which specifically recognizes aglyco protein 10B.

Claim 15 (original): A therapeutic composition for increasing antimalignin antibody concentration in a patient in need thereof comprising a peptide selected from the group consisting of a peptide of SEQ ID NO:1, a peptide of SEQ ID NO:2, aglycoprotein 10B, and combinations thereof.

Claim 16-23 (canceled).

Claim 24 (currently amended): A kit for determining the concentration of aglycoprotein 10B antigenic epitopes present in blood of a patient comprising at least one blood collection tube or pipette and antigmalignin antibody ~~The kit according to claim 24~~ wherein said antibody is coated on the inner surface of the said test tube or pipette.

Claim 25 (original): A kit for determining the concentration of anti-malignin antibody present in blood of a patient comprising at least one blood collection tube or pipette and peptide having the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

Claim 26 (currently amended): The kit of claim ~~[[23]]~~ 25 wherein the peptide is coated on the inner surface of the tube or pipette.

Claim 27 (original): An isolated nucleic acid encoding a peptide comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

Claims 28-31 (canceled).